Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- SystImmune, Inc.SystImmune, Inc. to Present New Global Data on Iza-bren (izalontamab brengitecan) in EGFR-mutated Non-Small Cell Lung Cancer at WCLC Congress 2026- New global Phase 1 data from a randomized dose-expansion cohort of iza-bren in previously treated EGFR-mutated metastatic NSCLC demonstrate promising antitumor activity and a tolerable safety profile, supporting selection of 2.5 mg/kg D1D8 Q3W as the recommended Phase 3 dose REDMOND,...
- Kahn Swick & Foti, LLCCapricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineKahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NasdaqGS: CAPR) of a class action...
- AI in Diagnostic Imaging Market Size to Reach USD 24.73 Billion by 2035 Growing at a CAGR of 23.83% - SNS InsiderU.S. AI in Diagnostic Imaging Market to Reach USD 8.28 Billion and Europe USD 6.22 Billion by 2035 as Cloud-Based Radiology, Oncology Imaging, and Workflow Automation Drive Growth.
- BetterLife Pharma Inc.BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded WarrantsFINAL PROSPECTUS ACCESSIBLE ON SEDAR+Vancouver, British Columbia--(September 11, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, is pleased to announce today that it has filed a final short form prospectus (the "Final Prospectus") with the securities regulatory authorities in the provinces of British Columbia, Ontario and Alberta, in connection with the previously announced...
- FDA Approves Isembyld (apitegromab-mstn), the First and Only Muscle-Targeted Therapy for Spinal Muscular Atrophy, Marking a New Milestone in SMA TreatmentThe Muscular Dystrophy Association (MDA) marks another milestone for the neuromuscular community with the U.S. Food and Drug Administration (FDA) approval of Isembyld (apitegromab-mstn), a monthly infusion treatment for people living with spinal muscular atrophy (SMA) who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment. Isembyld (apitegromab-mstn) is the first and only muscle-targeted therapy for SMA, offering new hope for children and adults living with this neuromuscular disease. SMA is a leading genetic cause of death in infants and often requires lifelong support to maintain mobility, breathing, and independence. Today, with more treatments available, people are living longer, more independent lives. Read Scholar Rock’s announcement here.
- Robbins LLP Reminds Capricor Therapeutics, Inc. Stockholders of the Securities Fraud Class Action After the Company's Stock Fell 64%Robbins LLP is Investigating Allegations That Capricor Therapeutics, Inc. Misled Investors Regarding the Facts About the Path to FDA Approval for Deramioce
- Robbins LLP Reminds Investors of the Securities Fraud Class Action Lawsuit Against ARS Pharmaceuticals Inc. Following a More Than 23% Stock Drop on June 25, 2026Robbins LLP is Investigating Allegations that ARS Pharmaceuticals Misled Investors Regarding Their Business Prospects
- Ynvisible Interactive Inc.Ynvisible Advances Commercial Program with Sapphiros, Announces CFO Appointment and Adoption of Semi-Annual Financial ReportingYnvisible Interactive Inc. (TSXV: YNV) (FSE: 1XNA) (OTCQB: YNVYF) (the "Company" or "Ynvisible") is pleased to provide an update on its strategic collaboration with Sapphiros, a consumer diagnostics company developing next-generation digital diagnostic tests for global markets.Sapphiros is progressing through clinical trials, with completion expected in the fourth quarter of 2026, while advancing regulatory, product...
- MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that the Compensation Committee of the Board of Directors of MaxCyte granted inducement awards in the form of stock options to purchase an aggregate of 220,000 shares of MaxCyte’s common stock and a service-based restricted stock unit (“RSU”) award with respect to 110,000 shares of MaxCyte’s common stock to Sidharth Kapileshwar, in connection with his commencement of employment as Senior Vice-President, Chief Corporate Development Officer at MaxCyte. The awards were granted under the MaxCyte, Inc. 2026 Inducement Plan (the “Plan”) with a grant date of August 31, 2026 as an inducement material to entering into employment with MaxCyte, in accordance with Nasdaq Listing Rule 5635(c)(4).
- Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business UpdateCellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will host a conference call and webcast on Monday, September 14, 2026 to provide a business update.
- 4DMT Announces New Employment Inducement Grants4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on September 8, 2026, the compensation committee of the Company’s board of directors granted seven new non-executive employees 96,000 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
- Delcath Systems, Inc.Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)QUEENSBURY, N.Y., September 11, 2026--Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to four individuals whose employment commenced in either July 2026 or August 2026.